The Latest Cardiac and Vascular News
JACKSONVILLE, Fla. and IRVINE, Calif., June 4, 2020 /PRNewswire/ — Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today expanded a collaborative partnering effort for its lead product candidate tecarfarin. Tecarfarin is […]
JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today announced that the U.S. Food and Drug […]
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control, today announced that Lee’s Pharmaceutical Holdings Limited […]
JACKSONVILLE, Fla. and IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., (“Espero”, or “the Company”), a pharmaceutical company focused on the development of late-stage drugs to treat forms of cardiovascular disease, today announced the appointment of Lee […]
JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Quang Pham, Espero’s Chief Executive Officer, will present […]
